Status:
RECRUITING
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
Lead Sponsor:
JaxBio Ltd
Conditions:
Lung Cancer, Non-Small Cell
Eligibility:
All Genders
18+ years
Brief Summary
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer. The goal of this study is to develop a simple blood test...
Detailed Description
During cell death, which occurs frequently in cancerous tissue, DNA from the dead cells is released into the blood. This DNA has a unique epigenetic pattern that can indicate the tissue of origin from...
Eligibility Criteria
Inclusion
- Men and women over 18 years old.
- Patients diagnosed with lung cancer before systemic therapy.
- Patients with inconclusive LDCT findings.
- Healthy volunteers.
- Patients with chronic lung diseases (COPD, pulmonary emphysema, acute pneumonia).
Exclusion
- Subjects who did not sign a consent form.
- Patients with cancer other than lung cancer.
- Patients with HIV or hepatitis.
- Patients with active autoimmune diseases (except lung-localized diseases).
- Pregnant women or individuals unable to give informed consent.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06963307
Start Date
May 1 2025
End Date
November 1 2026
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel